Real-world efficacy of ribociclib (RIB) plus aromatase inhibitor (AI)/fulvestrant (FUL), or endocrine monotherapy (ET), or chemotherapy (CT) as first-line (1L) treatment (tx) in elderly patients (pts; > 75 years) with hormone receptor-positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC): Results of fifth interim analysis (IA) from RIBANNA

被引：0
|
作者：
Decker, Thomas
Brucker, Cosima
Engel, Anne
Fasching, Peter A.
Goehler, Thomas
Jackisch, Christian
Janssen, Jan
Koehler, Andreas
Luedtke-Heckenkamp, Kerstin
Lueftner, Diana
van Mackelenbergh, Marion
Marme, Frederik
Nusch, Arnd
Rautenberg, Beate
Reimer, Toralf
Schmidt, Marcus
Weide, Rudolf
Wimberger, Pauline
Roos, Christian
Woeckel, Achim
机构：
[1] Onkol Ravensburg, Ravensburg, Germany
[2] Paracelsus Med Univ, Univ Womens Hosp, Nurnberg, Germany
[3] Winicker Norimed GmbH, Nurnberg, Germany
[4] Univ Hosp Erlangen, Dept Obstet & Gynecol, Erlangen, Germany
[5] Onkozentrum Dresden Freiberg, Dresden, Germany
[6] Sana Klinikum Offenbach, Dept Obstet & Gynecol, Offenbach, Germany
[7] Med Studiengesell Nord West GmbH, Westerstede, Rhauderfehn, Germany
[8] Practice Hematol & Oncol, Langen, Germany
[9] Niels Stensen Kliniken, Dept Hematol & Oncol, Georgsmarienhutte, Germany
[10] Med Univ Brandenburg, Immanuel Klin Markische Schweiz, Buckow, Germany
[11] Univ Klinikum Schleswig Holstein, Kiel, Germany
[12] Heidelberg Univ, Med Fak Mannheim, Mannheim, Germany
[13] Practice Hematol & Internal Oncol, Velbert, Germany
[14] Univ Klinikum Freiburg, Freiburg, Germany
[15] Univ Klinikum Rostock, Rostock, Germany
[16] Johannes Gutenberg Univ Mainz, Klin & Poliklin Geburtshilfe & Frauengesundheit, Mainz, Germany
[17] InVO GbR, Koblenz, Germany
[18] Tech Univ Dresden, Univ Klinikum Carl Gustav Carus, Dresden, Germany
[19] Novartis Pharma GmbH, Nurnberg, Germany
[20] Univ Wurzburg, Dept Gynecol & Obstet, Wurzburg, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e13050
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Survival among patients with hormone receptor positive (HR plus )/human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer: A real-world observational study
    Engel-Nitz, N. M.
    Hao, Y.
    Rey, G. Gomez
    Sullivan, J.
    Rogerio, J. Willemann
    CANCER RESEARCH, 2013, 73
  • [32] Safety results of the Canadian Expanded Access Program (EAP) of palbociclib (PAL) plus letrozole (L) in postmenopausal patients (pts) with hormone receptor-positive (HR plus )/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) deemed appropriate candidates for first-line (1L) endocrine therapy (ET) with L.
    Joy, Anil A.
    Verma, Shailendra
    Provencher, Louise
    Theall, Kathy Puyana
    Lu, Dongrui
    Dequen, Florence
    Rayson, Daniel
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [33] RIBOCICLIB (RIB) plus LETROZOLE (LET) IN PATIENTS WITH HORMONE RECEPTOR-POSITIVE (HR plus ), HUMAN EPIDERMAL RECEPTOR-2-NEGATIVE (HER2-) ADVANCED BREAST CANCER (ABC) BY DOSE INTENSITY: PRELIMINARY SUBGROUP RESULTS FROM THE PHASE 3B COMPLEEMENT-1 TRIAL
    Farhat, Fadi
    Martin, Miguel
    Campone, Mario
    Bachelot, Thomas
    Neven, Patrick
    Martinez Rodriguez, Jorge Luis
    Yusof, Mastura Md
    Papazisis, Konstantinos
    Ferreira, Ana
    Ankrah, Nii
    Wu, Jiwen
    Zhou, Katie
    De laurentiis, Michelino
    BREAST, 2019, 48 : S46 - S46
  • [34] COST-EFFECTIVENESS OF RIBOCILIB PLUS FULVESTRANT (R plus F) VS FULVESTRANT (FUL) IN HORMONE RECEPTOR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HR+/HER2-) ADVANCED BREAST CANCER (ABC): A CANADIAN HEALTHCARE PERSPECTIVE
    Stellato, D.
    Thabane, M.
    Chandiwana, D.
    Lanoue, B.
    Delea, T. E.
    VALUE IN HEALTH, 2020, 23 : S45 - S45
  • [35] Ribociclib plus letrozole in premenopausal patients with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Subgroup analysis of the phase IIIb CompLEEment-1 trial
    Razeq, Hikmat Abdel
    Cottu, Paul
    Ring, Alistair
    De laurentiis, Michelino
    Lu, Janice
    Azim, Hamdy
    Zamagni, Claudio
    Zhou, Katie
    Wu, Jiwen
    Menon-Singh, Lakshmi
    Martin, Miguel
    CANCER RESEARCH, 2021, 81 (04)
  • [36] Real-world effectiveness of alpelisib (ALP) plus fulvestrant (FUL) compared with standard treatment among patients (Pts) with hormone-receptor positive (HR plus ) human epidermal growth factor receptor-2 negative (HER2-) PIK3CA-mutated (Mut) advanced breast cancer (ABC)
    Turner, S.
    Chia, S. K. L.
    Kanakamedala, H.
    Hsu, W-C.
    Park, J.
    Chandiwana, D.
    Ridolfi, A.
    Yu, C-L.
    Zarate, J. P.
    Rugo, H. S.
    ANNALS OF ONCOLOGY, 2020, 31 : S366 - S366
  • [37] Ribociclib plus letrozole in male patients with hormone receptor-positive (HR plus ), human epidermal growth factor receptor-2negative (HER2-) advanced breast cancer (ABC): Subgroup analysis of the phase IIIb CompLEEment-1 trial
    Campone, Mario
    De Laurentiis, Michelino
    Zamagni, Claudio
    Kudryavcev, Igor
    Agterof, Mariette
    Brown-Glaberman, Ursa
    Palacova, Marketa
    Chatterjee, Sanjoy
    Menon-Singh, Lakshmi
    Wu, Jiwen
    Zhou, Katie
    Martin, Miguel
    CANCER RESEARCH, 2021, 81 (04)
  • [38] Ribociclib plus endocrine therapy (ET) doublet combinations in hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Phase I clinical activity and impact of molecular alterations
    Julie, Dejan
    Campone, Mario
    Munster, Pamela
    Ismail-Khan, Roohi
    Estevez, Laura Garcia
    Chavez-MacGregor, Mariana
    Frassoldati, Antonio
    Hui, Rina
    Mayer, Ingrid A.
    Cortes, Javier
    Goncalves, Anthony
    De Boer, Richard H.
    Dirix, Luc
    Tolaney, Sara M.
    Lee, Soo Chin
    Maur, Michela
    Wang, Yingbo
    Su, Faye
    Dobson, Jason R.
    Germa, Caroline
    Hewes, Becker
    Bardia, Aditya
    CANCER RESEARCH, 2017, 77
  • [39] Alpelisib (ALP) plus endocrine therapy (ET) in patients (pts) with PIK3CA-mutated hormone receptor-positive (HR plus ), human epidermal growth factor-2-negative (HER2-) advanced breast cancer (ABC): First interim BYLieve study results.
    Rugo, Hope S.
    Borrego, Manuel Ruiz
    Chia, Stephen K. L.
    Juric, Dejan
    Turner, Nicholas C.
    Drullinsky, Pamela
    Lerebours, Florence
    Bianchi, Giulia Valeria
    Nienstedt, Carolyn C.
    Ridolfi, Antonia
    Thuerigen, Astrid
    Ciruelos, Eva
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [40] Real-world treatment duration of subsequent therapy after palbociclib (PAL) in patients with hormone receptor-positive (HR plus )/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) in Japan
    Sawaki, Masataka
    Muramatsu, Yasuaki
    Togo, Kanae
    Iwata, Hiroji
    CANCER RESEARCH, 2023, 83 (05)
12345